Due to the heterogeneity of breast cancer and the fact that each breast cancer molecular subtype represents a distinct entity in its clinical, molecular and therapeutic management, the co-expression levels of PRLR with both TGFβ receptors in different breast cancer molecular subtypes were evaluated using the same panel of TMA and the same classification methods used previously [10,16]. This evidence concerns the gene PRLR and breast carcinoma.